Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day


News provided by

ThromboGenics

20 Oct, 2011, 16:10 GMT

Share this article

Share toX

Share this article

Share toX

LEUVEN, Belgium, October 20, 2011 /PRNewswire/ --

Leading retinal specialist also invited to present ocriplasmin responder analysis for the treatment of macular holes at Best of the Posterior Segment Specialty Meetings

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that three leading retinal specialists will present the responder analysis on ocriplasmin, a potentially novel treatment for retinal disorders, at the 2011 AAO Annual Meeting in Orlando, USA (21-25 October 2011).

The presentations include the opening session of the Retina Subspecialty Day by Dr Julia Haller, Ophthalmologist-in-Chief at the Wills Eye Institute, Professor and Chair of the Department of Ophthalmology at Thomas Jefferson University. The Retina Subspecialty Day aims to provide up-to-date, relevant topics and insights into new treatments for retina specialists from around the world.    

In addition, Dr Peter Kaiser has been selected to present his paper on ocriplasmin for the treatment of macular holes at the Best of the Posterior Segment Specialty Meetings. This presentation has been selected by the AAO Special Projects Committee based on the best data presentations from major retina meetings during 2011. Dr Kaiser presented a review of these data at the American Society of Retina Specialists (ASRS; please see press release dated 22 August 2011).    

Details of the presentations are as follows:

- Retina Subspecialty Day
Dr. Julia Haller: The Vitreomacular Interface and Ocriplasmin 2011
21 October: 8.05-8.12am; Valencia Room W415abc

- AAO General Session
Dr. Pravin Dugel: A New Pharmacologic Option for the Treatment of Symptomatic Vitreomacular Adhesions: Phase III Clinical Trial Results of Ocriplasmin from the MIVI-TRUST Program
24 October: 10.27-11.00am; Room W414cd

- AAO General Session, Best of the Posterior Segment Specialty Meetings 2011
Dr. Peter Kaiser: Ocriplasmin for the Treatment of Macular Holes: Results From the MIVI-TRUST Phase III Program
25 October: 12.15-1.00pm; Room W311

Dr. Julia Haller, Ophthalmologist-in-Chief of the Wills Eye Institute, Professor and Chair of the Department of Ophthalmology at Thomas Jefferson University, said: "I am delighted to be the lead-off batter for this year's Retina Subspecialty Day, presenting the latest data on clinical trials of ocriplasmin, a novel vitreolytic agent that has the potential to offer a minimally invasive pharmacological approach to diseases of the vitreoretinal interface. As a retina surgeon in clinical practice for over 25 years, it is exciting to see the possibilities that ocriplasmin may offer us as a nonsurgical, potentially earlier and safer approach to sight-threatening disorders."

Dr Patrik Haes, CEO of ThromboGenics, added: "The continued and growing support from the international retinal community highlights their interest in ocriplasmin's potential to pharmacologically treat patients with symptomatic VMA including macular hole. We are making solid progress to bring ocriplasmin to market, with the review of the EMA marketing authorization application under way and a filing with the U.S. FDA planned by the end of the year."

The AAO is the largest U.S membership association of ophthalmologists. It also includes more than 7,000 international members. Its annual meeting is the largest gathering of ophthalmologists in the world, with approximately 10,000 attendees at the 2011 meeting.

Ocriplasmin is a novel pharmacological agent for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. Symptomatic VMA is a progressive condition that if left untreated generally leads to further decrease in vision and potential for irreversible damage as well as complications. Market research conducted by ThromboGenics suggests that there are approximately a total of 500,000 patients in the major markets of the EU and the US who could initially benefit from ocriplasmin. The Marketing Authorization Application for ocriplasmin has been accepted for review in Europe. If approved, ocriplasmin will be the first pharmacological treatment for a condition which is currently only treated when the disease progresses to significant complications and symptoms that warrant surgery.

Biographies

Dr Julia Haller, MD, is Ophthalmologist-in-Chief of the Wills Eye Institute, Professor and Chair of the department of ophthalmology at Thomas Jefferson University. She has published over 250 papers in peer-reviewed literature and over 20 book chapters. She is past president of the ASRS and is on the editorial boards of RETINA, Retinal Physician, Ocular Surgery News, Ophthalmology Times, and Evidence-Based Ophthalmology.  

Dr Peter K. Kaiser, MD, is Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine, and Founder and Director of the Digital Optical Coherence Tomography Reading Center. He is Study Chairman of five international clinical trials and Principal Investigator in several other trials. Dr Kaiser has authored seven textbooks, 25 book chapters, and more than 150 peer-reviewed manuscripts.

Dr Pravin U. Dugel, M.D, is Managing Partner of Retinal Consultants of Arizona and Clinical Associate Professor at the Doheny Eye Institute, Keck School of Medicine, University of Southern California in Los Angeles. He has delivered numerous named lectures internationally and has served as primary investigator in many National Eye Institute research studies. Dr Dugel has authored more than 200 papers and book chapters.  

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative ophthalmic medicines. The Company's lead product ocriplasmin has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The Marketing Authorization Application for ocriplasmin has been accepted for review in Europe and the BLA is expected to be filed in the U.S. by the end of 2011. Ocriplasmin is also in Phase II clinical development for additional vitreoretinal conditions.

ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International. These include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact:

ThromboGenics
Dr. Patrik De Haes, CEO
Tel: +32-16-75-13-10
patrik.dehaes@thrombogenics.com


Chris Buyse, CFO
Tel: +32-16-75-13-10
chris.buyse@thrombogenics.com

Citigate Dewe Rogerson
David Dible/ Nina Enegren/ Sita Shah
Tel: +44(0)207-638-95-71
nina.enegren@citigatedr.co.uk

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.